Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

Saved in:

Bibliographic Details
Main Authors:	Sandhya Vasan, Supachai Rerks-Ngarm, Peter Gilbert, Barton Haynes, Sorachai Nitayapan, Punnee Pitisuttihum, Jaranit Kaewkungwal, Jean Louis Excler, Merlin Robb, Nelson Michael, Jerome Kim, Robert O’Connell
Other Authors:	Armed Forces Research Institute of Medical Sciences, Thailand
Format:	Letter
Published:	2018
Subjects:	Immunology and Microbiology
Online Access:	https://repository.li.mahidol.ac.th/handle/123456789/36173
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Mahidol University

Similar Items

Comparison of antibody responses induced by RV144, VAX003, and VAX004 vaccination regimens
by: Chitraporn Karnasuta, et al.
Published: (2018)

Accuracy of clinical diagnosis of dengue episodes in the RV144 HIV vaccine efficacy trial in Thailand
by: Punnee Pitisuttithum, et al.
Published: (2018)

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees
by: Ickwon Choi, et al.
Published: (2018)

HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial
by: Heather A. Prentice, et al.
Published: (2018)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
by: Stephanie Fischinger, et al.
Published: (2020)

RV144 HIV-1 vaccination impacts postinfection antibody responses
by: Thembi Mdluli, et al.
Published: (2020)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee
by: Nathan I. Nicely, et al.
Published: (2018)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
by: Siriwat Akapirat, et al.
Published: (2019)

RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
by: Eric Lewitus, et al.
Published: (2022)

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial
by: Shuying S. Li, et al.
Published: (2018)

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144
by: Merlin L. Robb, et al.
Published: (2018)

CD8 and CD4 epitope predictions in RV144: No strong evidence of a T-cell driven sieve effect in HIV-1 Breakthrough sequences from trial participants
by: Kalpana Dommaraju, et al.
Published: (2018)

The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
by: Nicos Karasavvas, et al.
Published: (2018)

Monoclonal antibodies, derived from humans vaccinated with the RV144 HIV vaccine containing the HVEM binding domain of herpes simplex virus (HSV) glycoprotein D, neutralize HSV infection, mediate antibody-dependent cellular cytotoxicity, and protect mice from ocular challenge with HSV-1
by: Kening Wang, et al.
Published: (2018)

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
by: Pinghuang Liu, et al.
Published: (2018)

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
by: David C. Montefiori, et al.
Published: (2018)

HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of the RV144 Thai vaccine efficacy trial
by: K. M. Baldwin, et al.
Published: (2018)

Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial
by: Punnee Pitisuttithum, et al.
Published: (2020)

Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial
by: Punnee Pitisuttithum, et al.
Published: (2020)

Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
by: Paul T. Edlefsen, et al.
Published: (2018)

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability
by: Shubin Z.
Published: (2023)

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope
by: Mark S. De Souza, et al.
Published: (2018)

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved
by: Kevin Wiehe, et al.
Published: (2018)

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines
by: Amy W. Chung, et al.
Published: (2018)

Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
by: Munir S. Alam, et al.
Published: (2018)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
by: Slim Fourati, et al.
Published: (2020)

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
by: Raphael Gottardo, et al.
Published: (2018)

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial
by: David Easterhoff, et al.
Published: (2018)

Novel strategy to adapt simian-human immunodeficiency virus e1 carrying env from an rv144 volunteer to rhesus macaques: Coreceptor switch and final recovery of a pathogenic virus with exclusive r5 tropism
by: Hanna B. Scinto, et al.
Published: (2019)

Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response
by: Stephanie Fischinger, et al.
Published: (2020)

HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX ® B/E
by: Robert Paris, et al.
Published: (2018)

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand
by: Punnee Pitisuttithum, et al.
Published: (2018)

Vaccine development lessons between HIV and COVID-19
by: Sandhya Vasan, et al.
Published: (2022)

Modulation of vaccine-induced CD4 T cell functional profiles by changes in components of HIV vaccine regimens in humans
by: Franco Pissani, et al.
Published: (2019)

Boosting with AIDSvax B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity breadth and potency
by: David Easterhoff, et al.
Published: (2020)

Identification of immunodominant cd4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E
by: Silvia Ratto-Kim, et al.
Published: (2018)

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women
by: Peter B. Gilbert, et al.
Published: (2018)

Expanding research capacity and accelerating AIDS vaccine development in Asia
by: Jean Louis Excler, et al.
Published: (2018)

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
by: Holly Janes, et al.
Published: (2018)

Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand
by: Trevor A. Crowell, et al.
Published: (2022)